Show simple item record

dc.contributor.authorKanai, Yuta
dc.contributor.authorVan Rijn, Piet A.
dc.contributor.authorMaris-Veldhuis, Mieke
dc.contributor.authorKaname, Yuki
dc.contributor.authorAthmaram, T.N.
dc.date.accessioned2016-03-11T12:17:00Z
dc.date.available2016-03-11T12:17:00Z
dc.date.issued2014
dc.identifier.citationKanai, Y. et al. 2014. Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus. Vaccine, 32(39):4932-4937. [https://doi.org/10.1016/j.vaccine.2014.07.031]en_US
dc.identifier.issn0264-410X
dc.identifier.issn1873-2518 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/16645
dc.identifier.urihttps://doi.org/10.1016/j.vaccine.2014.07.031
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0264410X14009578
dc.description.abstractAfrican horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses.The causative agent AHS virus (AHSV) is transmitted by species of Culicoides. AHSV serogroup within thegenus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein,and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nineserotypes were expressed individually by the baculovirus expression system and the immunogenicity ofeach was studied by immunization of guinea pigs with single VP2 as well as with cocktails of VP2 proteins.Homologous neutralizing antibodies measured by 50% plaque reduction assay showed varying degrees(from 37 to 1365) of titers for different VP2 proteins. A low cross-neutralizing antibody titer was foundfor genetically related AHSV serotypes. Immunization with VP2 cocktails containing equal amounts ofeach of the VP2 proteins also triggered neutralizing antibodies albeit to lower titers (4-117) to each ofthe serotypes in the cocktail. This study is a first step to develop a VP2 subunit vaccine for AHS and ourresults indicate that VP2 subunit vaccines are feasible individually or in a multi-serotype cocktailen_US
dc.description.sponsorshipEU (FP7, ORBIVAC, number245266) and Biotechnical and Biological Sciences Research Council(Grant number BB/K015168/1)en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectAfrican horse sicknessen_US
dc.subjectRecombinant proteinen_US
dc.subjectCapsid protein VP2en_US
dc.subjectSubunit vaccineen_US
dc.titleImmunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virusen_US
dc.typeArticleen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record